Observational studyDigestive diseases and sciences2017
Gastrointestinal Bleeding Due to Gastrointestinal Tract Malignancy: Natural History, Management, and Outcomes.
Observational study in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 65 citations in OpenAlex.
- Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis.Annals of hematology · 2026Article
- Hemorrhagic Complications in Gastric Cancer: Current Evidence and Multidisciplinary Management Strategies.Cancers · 2026Review
- Transarterial Embolization for Malignancy-Related Gastrointestinal Bleeding: Outcomes with and Without CT Extravasation.Diagnostics (Basel, Switzerland) · 2026Article
- Altered mental status in cancer-related emergency hospitalizations: prevalence and recorded reasons for admission.BMC emergency medicine · 2026Article
- Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer.Cancer medicine · 2026Observational
- Endoscopic Management of Malignancy-Related Gastrointestinal Bleeding: A Comprehensive Narrative Review.Medical sciences (Basel, Switzerland) · 2026Review
- Immune checkpoint inhibitor exposure and outcomes of gastrointestinal bleeding in cancer patients: a national analysis of 130,557 hospitalizations, 2018-2022.Frontiers in medicine · 2026Article
- Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost-utility analysis in the United Kingdom.Endoscopy · 2025Article
- DNA Methylation Biomarker Discovery for Colorectal Cancer Diagnosis Assistance Through Integrated Analysis.Cancer informatics · 2025Article
- The Impact of Tumor Stage and Histopathology on Survival Outcomes in Esophageal Cancer Patients over the Past Decade.Medical sciences (Basel, Switzerland) · 2024Article
- Upper gastrointestinal bleeding as a warning sign of gastrointestinal cancer.Preventive medicine reports · 2024Article
- Efficacy of Endoscopic Tissue Adhesive in Patients with Gastrointestinal Tumor Bleeding.Digestive diseases and sciences · 2024Article
- Hemostatic radiotherapy for bleeding gastrointestinal tumors.World journal of gastrointestinal oncology · 2024Article
- Mortality Risk Scoring System in Patients after Bleeding from Cancers in the Upper Gastrointestinal Tract.Gut and liver · 2024Article
- Article
- Uncommon, overlooked and underreported causes of upper gastrointestinal bleeding.Intractable & rare diseases research · 2023Review
- Hemostatic Powders in Non-Variceal Upper Gastrointestinal Bleeding: The Open Questions.Medicina (Kaunas, Lithuania) · 2023Review
- Clinical characteristics and risk factors for 30-day mortality in esophageal cancer patients with upper gastrointestinal bleeding: a multicenter study.Frontiers in oncology · 2023Article
- Gastrointestinal hemorrhage in the setting of gastrointestinal cancer: Anatomical prevalence, predictors, and interventions.World journal of gastrointestinal endoscopy · 2021Article
- Upper gastrointestinal bleeding as the initial manifestation of gastroenteropancreatic neuroendocrine tumors.Proceedings (Baylor University. Medical Center) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) tumor bleeding can vary from occult bleeding to massive hemorrhage and can be the presenting sign of malignancy.
aimsOur primary aims were to: (1) characterize the natural history, treatment, and outcomes in patients with GI tumor bleeding and (2) compare and contrast bleeding in upper GI (UGI)/small bowel (SB) and lower GI malignancies.
methodsPatients with endoscopically confirmed tumor bleeding were identified through search of consecutive electronic medical records: Bleeding was determined by the presence of melena, hematochezia, hematemesis, or fecal occult blood. Comprehensive clinical and management data were abstracted.
resultsA total of 354 patients with GI tumors were identified: 71 had tumor bleeding (42 UGI/SB and 29 colonic). GI bleeding was the initial presenting symptom of malignancy in 55/71 (77%) of patients; 26/71 patients had widely metastatic disease at presentation. Further, 15 of 26 patients with metastatic disease presented with GI bleeding. Visible bleeding was present in 14/42 (33%) and 4/29 (14%) of UGI/SB and colonic tumors, respectively. Endoscopic hemostasis was attempted in 10 patients, and although initial control was successful in all, bleeding recurred in all of these patients. The most common endoscopic lesion was clean-based tumor ulceration. Overall mortality at 1 year was 57% for esophageal/gastric, 14% for SB, and 33% for colonic tumors.
conclusionsWhen patients with GI malignancy present with GI bleeding, it is often the index symptom. Initial endoscopic hemostasis is often successful, but rebleeding is typical. Esophageal and gastric tumors carry the poorest prognosis, with a high 1-year mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.